FDA approves Lupin’s generic Tamiflu for oral suspension
The Food and Drug Administration has approved Lupin’s generic Tamiflu for oral suspension (oseltamivir phosphate for oral suspension, 6 mg/ml). Lupin said it would shortly begin promoting the product.
Lupin’s generic Tamiflu for oral suspension is inficated to treat acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours and prophylaxis of influenza A and B in patients ages 1 year and older.
The product had U.S. sales of roughly $358 million for the 12 months ended October 2017, according to IQVIA data.
Lupin’s generic Tamiflu for oral suspension is inficated to treat acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours and prophylaxis of influenza A and B in patients ages 1 year and older.
The product had U.S. sales of roughly $358 million for the 12 months ended October 2017, according to IQVIA data.